Literature DB >> 8700125

Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling.

P P Lakhlani1, D M Lovinger, L E Limbird.   

Abstract

The alpha 2A-adrenergic receptor (alpha 2AAR), via its interaction with the pertussis toxin-sensitive Gi/G(o) class of G proteins, modulates multiple effector systems, including inhibition of adenylyl cyclase and Ca2+ channels and activation of K+ channels. Mutation of a membrane-embedded aspartate residue, highly conserved among G protein-coupled receptors, in the alpha 2AAR to asparagine (D79N alpha 2AAR) results in selective uncoupling of the receptor to K+ currents but retention of inhibition of cAMP production and of voltage-sensitive Ca2+ currents when expressed in AtT20 anterior pituitary cells in culture. It is known that attenuation of cAMP synthesis alone cannot account for alpha 2AAR suppression of stimulus-secretion coupling; thus, the D79N alpha 2AAR provides a unique tool with which to assess the relative contribution of K+ current activation and Ca2+ current suppression in mediating the cellular responses of alpha 2AAR. The wild-type alpha 2AAR suppresses basal and secretagogue-evoked adrenocorticotropic hormone (ACTH) release in a manner indistinguishable from response to the endogenous somatostatin receptor. In contrast, the D79N alpha 2AAR does not attenuate basal ACTH release and is only partially effective in suppressing ACTH secretion evoked by the secretagogue isoproterenol. Regulation of ACTH release evoked by 8-bromo-cAMP, which bypasses receptor regulation of cAMP synthesis, suggests that attenuation of cAMP production, although not sufficient for inhibition of ACTH secretion, nevertheless participates in a functionally relevant manner. Taken together, the present findings indicate that alpha 2AAR-mediated suppression of neuropeptide secretion requires concomitant regulation of K+ and Ca2+ currents in parallel with attenuation of cAMP production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700125

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo.

Authors:  P P Lakhlani; L B MacMillan; T Z Guo; B A McCool; D M Lovinger; M Maze; L E Limbird
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Authors:  Yonghua Zhang; Harold K Kimelberg
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

3.  G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors.

Authors:  T Wurch; F C Colpaert; P J Pauwels
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 4.  Control of intracellular calcium signaling as a neuroprotective strategy.

Authors:  R Scott Duncan; Daryl L Goad; Michael A Grillo; Simon Kaja; Andrew J Payne; Peter Koulen
Journal:  Molecules       Date:  2010-03-03       Impact factor: 4.411

Review 5.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

6.  Dominant-negative mutants identify a role for GIRK channels in D3 dopamine receptor-mediated regulation of spontaneous secretory activity.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Gen Physiol       Date:  2000-06       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.